Keywords: update, irbesartan, first, drug, oked, diabetic, renal
Update: Irbesartan first drug OKed for diabetic renal disease in Europe
Article | 08 July 2002
Sanofi-Synthelabo and Bristol-Myers Squibb's angiotensin II receptorantagonist Aprovel/Karvea (irbesartan) has been approved for a new indication in the European ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
